Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Gemcitabine 6Irinotecan 5Oxaliplatin 4Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3Specimen Handling 3Leucovorin 3Fluorouracil 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3palbociclib 2olaparib 2cobimetinib 2Radiosurgery 2Positron-Emission Tomography 2Oncolytic Virotherapy 2Nivolumab 2Ketamine 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Disulfides 2Cyclophosphamide 2Capecitabine 2Biopsy 2tremelimumab 1trastuzumab biosimilar HLX02 1toripalimab 1sonidegib 1semaglutide 1pimonidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pancreatic Neoplasms × Tomography × Clear all
NCT02683824 2023-09-21

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

Stanford University

Phase EARLY_PHASE1 Completed
21 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡